Study guide
7.4 Abnormal Uterine Bleeding, Gynecologic Infections, & Contraception/Menopause
Medical Council of Canada Qualifying Examination Part I MCCQE Part I
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview, Blueprint & Canadian Medical Practice
1.1 MCCQE Part I Format, Scoring (439 Scale), & Strategy 1.2 The MCC Blueprint Matrix: Dimensions of Care & Physician Activities 1.3 Canadian Healthcare System, CanMEDS Roles, & Interprofessional Care 1.4 Evidence-Based Medicine, Study Design, & Clinical Statistics
2 Chapter 2: Population Health, Health Promotion & Preventive Care
2.1 Canadian Task Force on Preventive Health Care (CTFPHC) Screening Guidelines 2.2 Immunization Schedules (NACI) & Vaccine-Preventable Diseases across Lifespan 2.3 Disease Prevention, Lifestyle Counselling, & Harm Reduction 2.4 Outbreak Management, Disease Surveillance, & Infection Control 2.5 Occupational, Environmental, & Travel Medicine in Canada
3 Chapter 3: Internal Medicine — Cardiovascular & Respiratory Systems
3.1 Hypertension Canada 2020/2025 Guidelines, Dyslipidemia, & Primary Prevention 3.2 Ischemic Heart Disease, Acute Coronary Syndromes, & Heart Failure Management 3.3 Arrhythmias, Valvular Heart Disease, & Infective Endocarditis 3.4 Asthma, COPD, & Respiratory Failure (CTS Guidelines) 3.5 Thromboembolic Disease (DVT/PE), Pneumonia, & Pleural Effusions
4 Chapter 4: Internal Medicine — GI, Endocrine, Renal & Hematology/Oncology
4.1 Gastrointestinal Disorders, Acute Abdomen, & Liver/Biliary Disease 4.2 Diabetes Canada 2020/2025 Guidelines & Glycemic Management 4.3 Thyroid, Adrenal, Pituitary, & Electrolyte Disturbances 4.4 Acute Kidney Injury (AKI), Chronic Kidney Disease (CKD), & Nephrology 4.5 Hematology, Anemia Evaluation, Transfusion Medicine, & Common Cancers
5 Chapter 5: General Surgery, Orthopedics, & Emergency Care
5.1 Surgical Evaluation, Preoperative Clearance, & Postoperative Complications 5.2 Trauma Management (ATLS Protocol) & Burns 5.3 Acute Surgical Conditions (Appendicitis, Cholecystitis, Bowel Obstruction) 5.4 Fractures, Dislocations, Joint Pain, & Musculoskeletal Emergencies 5.5 Vascular Emergencies, Wound Care, & Shock Recognition
6 Chapter 6: Pediatrics & Adolescent Health
6.1 Pediatric Growth, Developmental Milestones, & Well-Child Examinations 6.2 Neonatal Resuscitation, Jaundice, & Common Congenital Anomalies 6.3 Pediatric Respiratory Emergencies (Croup, Bronchiolitis, Asthma) 6.4 Common Pediatric Infections, Exanthems, & Fever of Unknown Origin 6.5 Pediatric Abdominal Pain, Dehydration, & Fluid Management
7 Chapter 7: Obstetrics & Gynecology
7.1 Routine Antepartum Care, Screening, & Prenatal Diagnosis (SOGC Guidelines) 7.2 Medical Complications of Pregnancy (Preeclampsia, Gestational Diabetes, Infections) 7.3 Labor, Intrapartum Management, & Postpartum Complications/Hemorrhage 7.4 Abnormal Uterine Bleeding, Gynecologic Infections, & Contraception/Menopause 7.5 Gynecologic Oncology & Pelvic Mass Evaluation
8 Chapter 8: Psychiatry & Mental Health
8.1 Mood Disorders (Depression, Bipolar) & Suicide Risk Assessment 8.2 Anxiety Disorders, OCD, PTSD, & Somatic Symptom Disorders 8.3 Psychotic Disorders & Schizophrenia Management 8.4 Substance Use Disorders, Withdrawal Syndromes, & Harm Reduction 8.5 Pediatric, Perinatal, & Geriatric Psychiatry (Cognitive Impairment / Delirium)
9 Chapter 9: Neurology, Rheumatology, & Dermatology
9.1 Acute Stroke, TIA, & Neurovascular Emergencies 9.2 Headaches, Seizures, Movement Disorders, & Neuromuscular Disease 9.3 Inflammatory Arthritides (RA, Gout, SpA) & Systemic Autoimmune Diseases (SLE, Vasculitis) 9.4 Common Dermatologic Conditions, Cutaneous Manifestations of Systemic Disease, & Skin Cancers 9.5 Musculoskeletal Soft Tissue Injuries, Back Pain, & Physical Medicine
10 Chapter 10: Legal, Ethical, & Professional Behaviours in Canadian Practice
10.1 Informed Consent, Capacity Assessment, & Substitute Decision-Making (CMPA) 10.2 Medical Confidentiality, Privacy Laws (PIPEDA/PHIPA), & Disclosure of Harm 10.3 CMA Code of Ethics, Professionalism, & Physician Health/Boundary Issues 10.4 Mandatory Reporting (Child/Elder Abuse, Driving Safety, Fitness to Practice) & Quality/Safety
7.4 Abnormal Uterine Bleeding, Gynecologic Infections, & Contraception/Menopause
Key Takeaways Explain This Topic AI
Abnormal Uterine Bleeding (AUB) in non-pregnant reproductive-aged women is evaluated using the FIGO PALM-COEIN framework: Structural (Polyp, Adenomyosis, Leiomyoma, Malignancy) vs Non-structural (Coagulopathy, Ovulatory, Endometrial, Iatrogenic, Not classified).
Any postmenopausal vaginal bleeding mandates evaluation via transvaginal ultrasound (TVUS) to assess endometrial thickness (≤4 mm rules out endometrial carcinoma with >99% NPV) or endometrial tissue sampling (Pipelle).
Pelvic Inflammatory Disease (PID) is diagnosed clinically by pelvic/cervical motion tenderness and treated empirically with Ceftriaxone 500 mg IM + Doxycycline 100 mg PO BID x 14d + Metronidazole 500 mg PO BID x 14d.
Combined hormonal contraceptives (CHCs) are strictly contraindicated (WHO MEC Category 4) in smokers aged ≥35 who smoke ≥15 cigarettes/day, individuals with VTE/PE history, severe HTN, or migraine with aura.
Menopausal Hormone Therapy (MHT) for systemic vasomotor symptoms requires combining systemic estrogen with a progestin in individuals with an intact uterus to prevent endometrial hyperplasia and carcinoma.
Last updated: July 2026
Abnormal Uterine Bleeding, Gynecologic Infections, Contraception, & Menopause
This section covers key gynecologic topics essential for MCCQE Part I, including abnormal uterine bleeding frameworks, vaginitis, pelvic inflammatory disease, contraceptive eligibility, and menopausal hormone therapy under SOGC guidelines.
Abnormal Uterine Bleeding (AUB) & PALM-COEIN Classification
Abnormal Uterine Bleeding (AUB) refers to bleeding from the uterine corpus that is abnormal in duration, frequency, regularity, or volume in non-pregnant reproductive-aged women.
FIGO PALM-COEIN System Structural Etiologies (PALM - Diagnosed by Imaging/Histology):
- P - Polyp (Endometrial or Cervical)
- A - Adenomyosis (Endometrial tissue within myometrium; enlarged globular tender uterus)
- L - Leiomyoma (Submucosal, Intramural, Subserosal fibroids)
- M - Malignancy & Hyperplasia (Endometrial intraepithelial neoplasia, carcinoma)
Non-Structural Etiologies (COEIN):
- C - Coagulopathy (von Willebrand disease, heavy menses since menarche)
- O - Ovulatory dysfunction (PCOS, hypothyroidism, hyperprolactinemia, perimenopause)
- E - Endometrial (Primary endometrial vascular repair dysfunction)
- I - Iatrogenic (Exogenous hormones, IUDs, anticoagulants)
- N - Not otherwise classified
- Diagnostic Workup of AUB
Exclude Pregnancy : Beta-hCG urine/serum test is the mandatory first step in any reproductive-aged woman presenting with AUB.
Laboratory Testing : CBC, ferritin, TSH, prolactin, coagulation testing (if heavy menses since menarche).
Pelvic Ultrasound : Transvaginal Ultrasound (TVUS) to assess structural lesions (fibroids, polyps, adenomyosis) and endometrial thickness.
Endometrial Biopsy (Pipelle) Indications:
Any woman aged ≥40 years presenting with AUB.
Women aged <40 years with risk factors for endometrial carcinoma (obesity, PCOS, long-standing unopposed estrogen, Lynch syndrome).
Any postmenopausal woman with bleeding and TVUS endometrial thickness >4 mm .
- Gynecologic & Pelvic Infections
- Differential Diagnosis of Vaginitis
Condition Pathogen Vaginal Discharge pH Microscopy Findings First-Line Treatment
Bacterial Vaginosis (BV) Gardnerella vaginalis & anaerobes Thin, homogenous, greyish-white; fishy odor >4.5 Clue cells (stippled epithelial cells); Positive KOH whiff test Metronidazole 500 mg PO BID × 7 days
Vulvovaginal Candidiasis Candida albicans Thick, white, curdy ("cottage cheese"); intense pruritus Normal ( <4.5 ) Pseudohyphae & budding yeast on 10% KOH prep Fluconazole 150 mg PO single dose OR topical azole
Trichomoniasis Trichomonas vaginalis (STI) Frothy, yellow-green, foul-smelling; strawberry cervix >4.5 Motile flagellated protozoa on wet mount Metronidazole 500 mg PO BID × 7 days (Must treat partner!)
Pelvic Inflammatory Disease (PID)
PID is an ascending polymicrobial infection of the upper female genital tract ( Neisseria gonorrhoeae , Chlamydia trachomatis , vaginal anaerobes).
Clinical Diagnosis (SOGC Criteria) : Empiric treatment should be initiated in sexually active young women experiencing pelvic/lower abdominal pain if one or more of the following minimum clinical criteria are present on pelvic exam:
- Cervical motion tenderness ("Chandelier sign")
- Uterine tenderness
- Adnexal tenderness
Outpatient Regimen : Ceftriaxone 500 mg IM single dose + Doxycycline 100 mg PO BID × 14 days + Metronidazole 500 mg PO BID × 14 days .
Inpatient Regimen Indications (SOGC): Pregnancy, tubo-ovarian abscess (TOA), severe illness/high fever, surgical emergencies cannot be ruled out, or failure/intolerance of oral outpatient therapy. Regimen: IV Cefotetan 2 g q12h + IV Doxycycline 100 mg q12h OR IV Clindamycin 900 mg q8h + IV Gentamicin .
Contraception & WHO Medical Eligibility Criteria (MEC)
SOGC endorses the WHO Medical Eligibility Criteria for contraceptive use.
Absolute Contraindications to Combined Hormonal Contraceptives (CHC: Pill, Patch, Ring)
Combined estrogen-progestin contraceptives carry thrombosis and vascular risks. They are MEC Category 4 (Unacceptable health risk) in:
Age ≥35 years AND smoking ≥15 cigarettes/day .
Severe hypertension ( SBP ≥160 or DBP ≥100 mmHg ) or vascular disease.
Current or past history of venous thromboembolism (VTE/PE) , known thrombophilia, or major surgery with prolonged immobilization.
Migraine with aura (focal neurological symptoms) at any age (significantly increases ischemic stroke risk).
History of ischemic heart disease, stroke, or complicated valvular heart disease.
Active breast cancer .
Severe cirrhosis, hepatocellular adenoma, or malignant liver tumors.
Diabetes mellitus with microvascular complications (retinopathy, nephropathy, neuropathy) or duration >20 years.
Long-Acting Reversible Contraception (LARC)
Levonorgestrel IUD (LNG-IUD / Mirena) : Highly effective (>99%). First-line medical treatment for AUB-L and AUB-A (reduces menstrual blood loss by >90%).
Copper IUD (Cu-IUD) : Non-hormonal option lasting 5–10 years. Also serves as the most effective emergency contraceptive when inserted within 5 days (120 hours) of unprotected intercourse.
Menopause & Menopausal Hormone Therapy (MHT)
Menopause is defined clinically as 12 consecutive months of amenorrhea without underlying pathology (average age in Canada: 51.5 years). Premature Ovarian Insufficiency (POI) is menopause occurring before age 40.
Indications for Menopausal Hormone Therapy (MHT)
SOGC guidelines state MHT is indicated for:
Moderate-to-severe vasomotor symptoms (hot flashes, night sweats).
Prevention of osteoporosis in symptomatic women <60 years old or within 10 years of menopause .
Genitourinary Syndrome of Menopause (GSM / vulvovaginal atrophy): Local low-dose vaginal estrogen is first-line.
SOGC Prescribing Rules for Systemic MHT
Intact Uterus : Systemic Estrogen + Progestin (or Bazedoxifene) MUST be prescribed. Unopposed systemic estrogen in a woman with a uterus causes endometrial hyperplasia and markedly increases endometrial adenocarcinoma risk.
Prior Hysterectomy : Estrogen-ONLY therapy is prescribed (progestin is unnecessary).
Contraindications to Systemic MHT
Unexplained vaginal bleeding, active VTE/PE, recent arterial thromboembolic event (MI/stroke), active liver disease, history of breast cancer, or known estrogen-dependent neoplasia.
SOGC Clinical Practice Pearls & Exam Traps
⚠️ EXAM TRAP : Any postmenopausal bleeding is endometrial cancer until proven otherwise ! Transvaginal ultrasound demonstrating endometrial thickness >4 mm requires immediate endometrial biopsy (Pipelle).
🩺 CLINICAL SCENARIO : A 38-year-old woman who smokes 20 cigarettes per day requests oral contraceptive pills for heavy menses. What is the most appropriate management based on SOGC guidelines?
CHCs are strictly contraindicated (Category 4) due to catastrophic VTE/stroke risk.
Counsel the patient on a Levonorgestrel IUD (LNG-IUD) , which provides superior contraception, treats her heavy menses, and avoids estrogenic thrombotic risk.